Interest of adjusting urine cannabinoids to creatinine level to monitor cannabis cessation therapy in heavy smokers with psychiatric disorders.
cannabinoids
creatinine
modeling
monitoring
psychiatry
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
01
02
2019
revised:
24
06
2019
accepted:
26
06
2019
pubmed:
2
7
2019
medline:
7
3
2020
entrez:
2
7
2019
Statut:
ppublish
Résumé
Up to 25% of hospitalized patients in a psychiatric department exhibit troubles linked to cannabis use. Weaning patients with psychiatric disorders off drugs of abuse requires specific care to improve their clinical outcome. The present study aims to develop a predictive model of urinary excretion of creatinine-normalized cannabinoids (U
Substances chimiques
Cannabinoids
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1453-1459Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
United Nations Office on drugs and crime, World Drug Report 2014 (United Nations publication, Sales No. E.14.XI.7).
United Nations Office on drugs and crime, World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6).
Koskinen J, Löhönen J, Koponen H, et al. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36(6):1115-1130.
Rabin RA, Kozak K, Zakzanis K, et al. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. Schizophr Res. 2017;9964(17):30265-30267.
Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 2006;28(2):155-163.
Ellis GM, Mann MA, Judson BA, Schramm NT, Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther. 1985;38(5):572-578.
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.
Lecompte Y, Perrin M, Salle S, Roussel O. Impact of lowering confirmatory test cutoff value in pre-enlistment urine cannabinoids screening: about five years experience in the French gendarmerie. J Anal Toxicol. 2012;36(8):569-574.
Lafolie P, Beck O, Blennow G, et al. Importance of creatinine analyses of urine when screening for abused drugs. Clin Chem. 1991;37(11):1927-1931.
Schwilke EW, Gullberg RG, Darwin WD, et al. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction. 2011;106(3):499-506.
Smith ML, Barnes AJ, Huestis MA. Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol. 2009;33(4):185-189.
Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(1):77.
R Core team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2017, Vienna, Austria. https://www.R-project.org/.
Pinheiro J, Bates D, DeBroy S, et al. Nlme: linear and nonlinear mixed effects models. 2017, R package version 3.1-131.
Goodwin RS, Darwin WD, Chiang CN, Shih M, Li SH, Huestis MA. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol. 2008;32(8):562-569.
Lamoureux F, Duflot T, Woillard J, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in invasive fungal infections. Int J Antimicrob Ag. 2016;47(2):124-131.
van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J Clin Psychopharmacol. 2014;34(2):256-260.
Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006;45(3):253-285.